a independent you, made knew the we're Thank that seven proud success. of part we've out engine company, was as we of we productive over an our set essential the building an past progress When years. Rick. And R&D
VENCLEXTA, to strongest the new industry market built brought RINVOQ, sales assets; delivered late-stage $X which IMBRUVICA, of our and to MAVYRET approximately ORILISSA, one billion in and clinical We've will in XXXX. over the in pipelines in profiles. collectively continue we growth SKYRIZI, assets six of their for very build long-term supporting lead differentiated their well are evidence as the body performing AbbVie indications significant These drive and
very generate rheumatoid sets are immunology, from we data SKYRIZI off them respectively. and in RINVOQ In arthritis apart continue set competitive strong start offerings. and And to psoriasis a that to clinical both
recently In achieving XX study, For COSENTYX to from XX% trial results superiority to positive COSENTYX week in COSENTYX. SKYRIZI at Phase XX% head-to-head of PASI psoriasis. patients demonstrated announced XX SKYRIZI example for SKYRIZI comparing with we X a to topline compared this
all almost of superiority sPGA the points. results PASI SKYRIZI's long-term response underscore PASI of demonstrated XX, These SKYRIZI levels XXX, to profile; end the and ability response clear week that of high at or at also on critical drive end durability ranked points XX. secondary including and components COSENTYX two to clear
approved indications continue will Phase also hem/onc support readouts important in franchise XXXX. for data we to our our and regulatory milestones additional with X oncology, In
We on we the for for a in ECOG in year with positive study based CHMP And first frontline FCR important label superiority opinion expect VENCLEXTA in untreated demonstrated IMBRUVICA this half previously the CLL. an to from to of patients recently of receive fit results received IMBRUVICA update CLL. which
for components of two think consider pipeline. important the growth sources When to beyond our we our current about recently indications of assets, late-stage it's approved
important into future. The disease will new And represent allow assets of markets. that to is that in will first programs of is our a drive large second additional attractive growth help assets and the a number areas us the set that new core support large
If look of new our de-risked to we strong move areas into based disease commercially have at data. with first number our that attractive on programs a opportunity existing see been we therapies,
results study response we HUMIRA For arthritis in from DMARD. which in RINVOQ and placebo recently RINVOQ one Phase an inadequate example least second both patients psoriatic announced for topline to X at to non-biologic the compared had who
and study, RINVOQ points, both primary both radiographic significant as end joint demonstrating and end key structure. doses of well points skin damage joint to this as inhibition impact In secondary all met of on a
dose. and response results arthritis our reported registrational superiority non-inferiority dose Detailed meeting on regulatory HUMIRA second year. data be ACRXX trial our for quarter the week submit demonstrated followed These also presented XXXX. with XX late the in expect to low expected will RINVOQ positive from applications high at we with at with first and upcoming medical last data the in to RINVOQ both pivotal psoriatic from studies in commercialization an the
for ankylosing planned Following global positive second based of XXXX the on half submissions our ACR November. data already discussions last in regulators, with approval at spondylitis presented are
important demonstrated of $XX segment In to and function imaging sales make psoriatic placebo. approximately significantly market symptoms spondylitis compared and improvements arthritis billion. in as well of this Together, global market up the study, greater with points rheumatology as ankylosing physical end RINVOQ an signs and
we will do this The indication. we for dermatitis to middle growth segment dermatology today. in year, be participate RINVOQ is of Phase data an see RINVOQ. X Moderate-to-severe market in that expect And important for a in also this of not area atopic large the
and In had demonstrated a on easy troublesome impact RINVOQ on one strong of this point composite effect very our symptoms the study, prominent Phase most of which is end Xb the a disease. itch
submissions the pivotal we Following submit this to year. readouts, global data plan regulatory later
both disease new Crohn's of we in in X from both In submissions Phase of with areas. registrational arthritis regulatory completion in this and SKYRIZI expect also disease for see the are studies nearing programs We for the several to psoriatic expected second year, XXXX. data indications half
disease And a growing and IBD be where $XX colitis, IBD global The levels approximately on need. efficacy and both in to of segment, alternatives. performance therapeutic the of mid-stage studies, unmet based with represents other ulcerative sales Crohn's drive higher including to we believe have segment significant potential RINVOQ SKYRIZI both is market there significant our billion. opportunity demonstrated a continues the than
we SKYRIZI areas areas atopic the to approved and currently plus Together for across RINVOQ is new expect such disease which full coverage HUMIRA dermatitis. have as major
market. strong the is to maintain With these billion leadership positioned AbbVie two its new well global medicines, in immunology $XX
Phase to the we well genetic t(XX;XX) in X initiate that growth a expect And underway. Phase we population. X new second the CANOVA now the is relapsed/refractory end myeloma asset of patients with expand this towards is to areas plan important our mutation in year, multiple relapsed/refractory study t(XX;XX) study into Another VENCLEXTA.
VENCLEXTA important biomarker-driven population promising patients The survival. become has transformed prolonged of high to Bcl-X. have early t(XX;XX) myeloma. and the very treatment express VENCLEXTA with levels this a seen and response high mid-stage phenotype potential B-Cell in progression-free in showing in like and rates overall in We've XX:XX an results trials option cells multiple
market that This seen $XX that biomarker-defined multiple important to for may XX% the VENCLEXTA. The we've be approximately of an makes VENCLEXTA. new up level particularly billion efficacy t(XX;XX) population opportunity of patients suggests responsive representing myeloma
will studies in X in begin XXXX. additional we to Phase two multiple diseases myeloma, addition Bcl-X-driven In
remain the is AML. experience fit in high in for risk first we but our at a who The study AML with population, on have received are transplant-ineligible Building cell initiating recurrence. patients stem transplant,
The higher-risk is second or Syndrome Myelodysplastic MDS.
transformation mortality of is associated stem and risk bone bleeding, acute of to morbidity the MDS with and leukemia. is cells a malignant to that significant marrow disease due infection
options. MDS clinical studies have role very early patients Some begin our Phase undergo later few will and transplant, Preclinical many but X patients with these a in studies support year. inhibition cell this VENCLEXTA Bcl-X treatment stem these And cannot. and for patients with
and of in expect in myelofibrosis. this and that frontline component XXXX therapies will the including; pipeline and Phase to Navitoclax second ABBV-XXX. important launch late-stage value our we X in new includes veliparib The second-line year be first studies XXXX in navitoclax, of entering half
to replaced malignant Myelofibrosis patients the bone option, is is in fibrotic approved Currently, bone JAKX the many with experience failure. disease marrow morbidity a therapeutic only mortality. inhibition which but is marrow treatment significant tissue leading despite progress and and
Bcl-xL treatment inhibitor volume. that demonstrated we Navitoclax the last Phase potential had inhibition a ASH who a first-in-class data from clone up transform failed presented responded by encouraging is II to to that causes JAKX on of in spleen At the disease. a based patients myelofibrosis with of to the the year, which study reduction XX% XX% navitoclax deleting
In and patients. responses to addition, these over deepened follow we time continue
cells previously marrow of fibrosis and the decreases studies malignant the cancer of tumors, also two Phase area presented from number in and data patients In X for solid disease supporting modification. veliparib potential breast frontline in BRCA the in ovarian cancer. we've reductions treated Navitoclax positive showed bone
to Data from combine treatment. cancer, to that studies and population with and only responsiveness. inhibition the be of prolongation earlier a the the veliparib these restricted with course significant PARP not progression-free biomarker inhibitor status in of use ovarian support chemotherapy of or in broader demonstrated two will combination frontline survival chemo In treat chemotherapy is PARP
regulatory Veliparib chemotherapy plan combine a Based cancer option. patients inhibitor authorities, from breast of on important veliparib global to an new option year. also treatment valuable this for be will feedback cancer with to submit offering the we applications be first half women these for will new outcomes. breast cancer veliparib only with platinum-based BRCA-positive giving in In better PARP BRCA provide ovarian and the to our treatment the potential
innovative be for and approach disease. our carbidopa subcutaneous we like to levodopa late-stage novel in advanced ABBV-XXX, delivery This a prodrugs And DUOPA options. progress making improvement through system would a our for good X pipeline, current program Phase and the enabled is neuroscience by approach treatment with transformative to efficacy Parkinson's delivering are
XXX DUOPA the to as currently Parkinson's addressed invasive data We'll commercialization stimulation. advanced XXXX. delivery has less potential brain therapies such population in expand pivotal system or program a for With from the significantly by more other the deep see non-surgical invasive in with XXXX patient anticipated
addition progress In we've our to pipeline. early-stage our advancing, programs late-stage tremendous also made building
next to over we're we're for beginning programs. several of And planning Following the pay-off. years, efforts proof-of-concept approximately readouts investment, years these data in three XX see
include think mix underlying to early a validated strong we on Our targets science to targets clinically is improve opportunity by of and supported highly exists agents. novel current pipeline designed an where
this of novel to high-potency activated the immune ABBV-XXXX, highlight I'll immunology, technology approach has without steroid clinical demonstrated by is effects. TNF-mediated steroid can shown we steroid has that efficacy. transformational In therapeutic its deliver dose drive cells uptake. conjugate that area And proprietary which our model systemic systems We've a XXXX anticipated that our the directly delivers at TNF work in to early potential
efficacy a lupus. this steroid RA, our this we IBD will to year. If serve across our data study reproduce conjugate has from see platform have diseases a potential later data and seen pre-clinically, of including the range wide We technology as clinical what
today. IBD, standard and us early-stage therapy assets of new multiple diseases program, JAK-BTK antagonist pathogenic our our areas roles our ones We data into in restate important to also in effective program; where portfolio allowing lupus thought targeting including RA, core no year care that exists are move disease for such as several this nodes in will are to CDXX play and scleroderma, proof-of-concept ABBV-XXX see and our from which other data ABBV-XXX both immunology
to to advance apoptosis what are learned a BX-HX-targeting of navitoclax on we apoptosis-inducing apoptosis promising venetoclax TRAIL, programs. cells. these most are novel on The number with antibody to uses building to of an ABBV-XXX, a solid which have ABBV-XXX, which and by we tumors; deliver advanced and a of designed ligand surface oncology, warhead In is clustering cancer Bcl-xL high-potency induce the
in combination We will data and XXXX see ABBV-XXX monotherapy for data XXXX. in
expect XXXX have in T preclinical well. we several development. promising data cell-redirecting in and more bispecifics a We proof-of-concept as number clinic In in very to see of for the ABBV-XXX immuno-oncology,
affinities epitope TNB-XXXB explore area. promising most our bispecifics in multiple allow myeloma us The very and in specificities of binding advanced are candidates HPN-XXX. different These optimize and these this programs benefit/risk BCMA [ph] to of to
novel pursuing tumor also modify several designed approaches are the We environment. to immunosuppressive
I its monoclonal Through important targeting reduces Here would immune tumor PD-X evasion lack TGF-beta tumors. correlated ABBV-XXX, and is our a GARP. highlight ABBV-XXX and signaling antibody TGF-beta-mediated immune of driver on effect GARP be thought is infiltrate to TGF-beta signaling within unresponsiveness. tumor of with an
addition, anti-inflammatory pro-inflammatory that data to designed is CDXX I TTX-XXX. adenosine would in inhibitor, important emerging plays our highlight to by ADP an evasion In immune this TTX-XXX Recently restore immunosuppression. signal tumor suggest environment. the reduce extracellular in and pro-inflammatory role ATP and converting tumor CDXX important
in for neuroscience disease. promising we several candidates and pipeline Alzheimer's the have Parkinson's early disease-modifying in our Lastly clinic
aimed our alpha-synuclein. programs to core important of we TREMX regulators programs well tau-directed addition disease at driver In and neuroinflammatory CDXX; Parkinson's have as in of a the pathology response as
development of So programs. significant continued in to summary, and we've our evolution see late-stage early-
few includes XX early- programs will next over We more the pipeline to XX development mid-stage have mature a years. that in studies in registrational late-stage have and nearly than programs that
performance call our turn and guidance. comments Rob the our on XXXX for to Rob? over With that XXXX I'll additional
